Fundraising Fox
/Companies
Sign in

Synthesize

Founded 2023 · 23 employees on LinkedIn · 4 known investors

Find your way into Synthesize

Sign up to see every warm intro you have to Synthesize

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Synthesize team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Synthesize develops generative AI models that simulate human tissue responses to drugs and diseases for clinical trial design. The company helps biotech and pharmaceutical development teams de-risk trials, identify biomarkers, and extend early-phase data by generating synthetic patient cohorts.

AI & Machine LearningBiotechDigital Health

Founders & leadership

Synthesize was founded in 2023 by Robert Bradley, PhD and Jeff Leek, PhD.

RBRobert Bradley, PhD
Robert Bradley, PhDFounder
JLJeff Leek, PhD
Jeff Leek, PhDFounder
AWAlice Walsh, PhD
Alice Walsh, PhDAlice Walsh holds a BS from MIT and a PhD in bioengineering from Penn, and has spent over a decade in drug development, including roles as VP of Translational Research at Pathos and positions at Bristol Myers Squibb and Janssen focused on clinical trial advancement. She is Chief Operating Officer at Synthesize, which develops AI models for simulating drug responses in patient populations.
GKGregory Koytiger, PhD
Gregory Koytiger, PhDGregory Koytiger, PhD, has spent the past 7 years leading machine learning teams working on Transformer-based models for biomedical NLP, clinical forecasting, and drug discovery. He is co-founder and CEO of Synthesize, which develops generative AI models simulating human tissue responses to support clinical trial design.
JL
Jeff LeekFounder
RB
Robert BradleyFounder
ABAriel Brumbaugh, PhD
Ariel Brumbaugh, PhDFounder
SSStein Setvik
Stein SetvikFounder
LRLiza Ray, MBA
Liza Ray, MBAFounder

Investors · 4

AI2 IncubatorreportedSeattle

How we know: press coverage · Not right? Tell us

Inner Loop CapitalreportedBaltimorevia Justin Label · inferred

How we know: funding news · press coverage · Not right? Tell us

Sahsen VenturesreportedSeattle

How we know: press coverage · Not right? Tell us

Related companies · 3

Recursion PharmaceuticalsRecursion applies computational and data-driven approaches to biological science, aiming to accelerate drug discovery and develop new treatments. The company combines life scientists and software engineers to solve problems at the intersection of biology and technology.
Twist BioscienceTwist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals. The platform enables faster and more affordable DNA synthesis at scale with customizable high-throughput capabilities.
Engage BioEngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.

Companies working in the same space as Synthesize.

In the news

Synthesize Bio Launches with $10M Seed Fundingfinsmes.com · Sep 2025

Frequently asked questions

What does Synthesize do?
Synthesize develops generative AI models that simulate human tissue responses to drugs and diseases for clinical trial design. The company helps biotech and pharmaceutical development teams de-risk trials, identify biomarkers, and extend early-phase data by generating synthetic patient cohorts.
Who founded Synthesize?
Synthesize was founded by Robert Bradley, PhD, Jeff Leek, PhD in 2023.
Who are Synthesize's investors?
Synthesize's investors include Madrona Venture Group, AI2 Incubator, Inner Loop Capital, Sahsen Ventures.